United Kingdom

People: Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

19 Feb 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Robin, Howard 

Mr. Howard W. Robin is President, Chief Executive Officer, Director of the Company. Mr. Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a director. From 1991 to 2001, Mr. Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc. (“Berlex”), a pharmaceutical products company that is a subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer. From 1984 to 1987, Mr. Robin was Director of Business Planning and Development at Berlex. He was a Senior Associate with Arthur Andersen & Co. prior to joining Berlex. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University and serves as a member of its Board of Trustees.

Basic Compensation

Total Annual Compensation, USD 2,539,890
Restricted Stock Award, USD 6,884,890
Long-Term Incentive Plans, USD --
All Other, USD 8,672,630
Fiscal Year Total, USD 18,097,400

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 591,667 8,703,750.00
Name Fiscal Year Total

Robert Chess


Howard Robin


Gilbert Labrucherie


John Nicholson


Jillian Thomsen


Stephen Doberstein

As Of  31 Dec 2017